Renal Cell Carcinoma (RCC) Clinical Trial
Official title:
THE ROLE OF 18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS
In renal cell carcinoma (RCC) patients, lymph node metastases detection and treatment are the most critical issues in daily clinical decision-making. Indeed, conversely to other oncological settings, a) nodal status imaging, b) sentinel node technique and c) standard lymphadenectomy have been demonstrated inadequate in the staging and management of RCC patients. A novel, accurate, standardized imaging technique is urgently needed in RCC setting to detect macro and micro nodal invasion, to identify those patients who are at higher risk of having nodal metastases, to accurately plan the best management. Recent studies suggested combining 18F-FAZA PET with CT scanning in the detection of cancer-induced hypoxia.The investigators propose to test 18F-FAZA PET-CT in detecting nodal metastases to improve the management of RCC patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
| Completed |
NCT02903914 -
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04687969 -
Multimodal Machine Learning Characterization of Solid Tumors
|
||
| Completed |
NCT00557609 -
Phase 2 Study in Patients With MiT Tumors
|
Phase 2 | |
| Recruiting |
NCT05891171 -
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT01235962 -
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
|
Phase 3 | |
| Terminated |
NCT02837991 -
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
|
Phase 1 | |
| Completed |
NCT00199888 -
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
|
Phase 1 | |
| Completed |
NCT03538028 -
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
|
Phase 1 | |
| Terminated |
NCT03549000 -
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
|
Phase 1 | |
| Completed |
NCT02178722 -
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05410509 -
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
|
N/A | |
| Completed |
NCT02646748 -
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT04187872 -
LITT and Pembrolizumab in Recurrent Brain Metastasis
|
Phase 1 | |
| Terminated |
NCT00520533 -
Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
|
Phase 1 | |
| Active, not recruiting |
NCT03260894 -
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
|
Phase 3 | |
| Completed |
NCT04375150 -
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
|
||
| Terminated |
NCT03311334 -
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05909995 -
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
|
Phase 1 | |
| Completed |
NCT01666353 -
PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy
|
Early Phase 1 |